NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 122 filers reported holding NURIX THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $267,601 | -33.1% | 34,046 | -14.9% | 0.00% | – |
| Q2 2023 | $399,730 | +34.7% | 40,013 | +19.7% | 0.00% | – |
| Q1 2023 | $296,858 | +1490.4% | 33,430 | +1866.5% | 0.00% | – |
| Q4 2022 | $18,666 | -45.1% | 1,700 | -35.3% | 0.00% | – |
| Q3 2022 | $34,000 | -10.5% | 2,626 | -11.3% | 0.00% | – |
| Q2 2022 | $38,000 | -74.7% | 2,960 | -72.4% | 0.00% | – |
| Q1 2022 | $150,000 | -75.3% | 10,726 | -48.8% | 0.00% | – |
| Q4 2021 | $607,000 | +38.9% | 20,956 | +44.0% | 0.00% | – |
| Q3 2021 | $437,000 | +4755.6% | 14,554 | +4448.1% | 0.00% | – |
| Q2 2021 | $9,000 | -97.9% | 320 | -97.7% | 0.00% | – |
| Q1 2021 | $430,000 | -72.5% | 13,815 | -70.9% | 0.00% | – |
| Q4 2020 | $1,562,000 | +27.0% | 47,507 | +34.8% | 0.00% | – |
| Q3 2020 | $1,230,000 | – | 35,246 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |